Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Nature Medicine

Volumn 20, Issue 11, 2014, Pages 1301-1309

  Sistigu, Antonella ^a,b,c,d   Yamazaki, Takahiro ^a,b,c   Vacchelli, Erika ^a,b,c   Chaba, Kariman ^b,e,f   Enot, David P ^b,e,f   Adam, Julien ^a   Vitale, Ilio ^g   Goubar, Aicha ^a,b   Baracco, Elisa E ^a,b,c   Remédios, Catarina ^a,b,c   Fend, Laetitia ^a,b,h   Hannani, Dalil ^a,b,c   Aymeric, Laetitia ^a,b,c   Ma, Yuting ^a,b,c   Niso Santano, Mireia ^a,b,c   Kepp, Oliver ^a,b,c   Schultze, Joachim L ⁱ   Tüting, Thomas ^j   Belardelli, Filippo ^d   Bracci, Laura ^d   La Sorsa, Valentina ^d   Ziccheddu, Giovanna ^d   Sestili, Paola ^d   Urbani, Francesca ^d   Delorenzi, Mauro ^k,l,m   Lacroix Triki, Magali ⁿ   Quidville, Virginie ^a   Conforti, Rosa ^a,b,o,p   Spano, Jean Philippe ^p   Pusztai, Lajos ^q   Poirier Colame, Vichnou ^a,b,o   Delaloge, Suzette ^a   Penault Llorca, Frederique ^r   Ladoire, Sylvain ^b,s,t   Arnould, Laurent ^b,s,t   Cyrta, Joanna ^a   Dessoliers, Marie Charlotte ^a,b   Eggermont, Alexander ^c   Bianchi, Marco E ^u   Pittet, Mikael ^v   Engblom, Camilla ^v   Pfirschke, Christina ^v   Préville, Xavier ^h   Uzè, Gilles ^w   Schreiber, Robert D ^x   Chow, Melvyn T ^y   Smyth, Mark J ^y,z   Proietti, Enrico ^d   André, Fabrice ^a,b,c   Kroemer, Guido ^a,b,f,aa   Zitvogel, Laurence ^a,c,o   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^h TRANSGENE S A   (France)

ⁱ UNIVERSITY OF BONN   (Germany)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^l EPFL   (Switzerland)

^m LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁿ INSTITUT CLAUDIUS REGAUD   (France)

^o Center of Clinical Investigations in Biotherapies of Cancer   (France)

^p PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^q YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r CENTRE JEAN PERRIN   (France)

^s CENTRE GEORGES FRANÇOIS LECLERC   (France)

^t UNIVERSITÉ DE BOURGOGNE   (France)

^u SAN RAFFAELE HOSPITAL   (Italy)

^v MASSACHUSETTS GENERAL HOSPITAL   (United States)

^w UNIVERSITÉ DE MONTPELLIER   (France)

^x WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^z UNIVERSITY OF QUEENSLAND   (Australia)

^aa HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; ALPHA INTERFERON RECEPTOR; ANTHRACYCLINE; BETA INTERFERON RECEPTOR; CISPLATIN; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEASE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; PATTERN RECOGNITION RECEPTOR; RIBONUCLEASE A; RIBONUCLEASE H; RIBONUCLEASE L; RNA POLYMERASE; TOLL LIKE RECEPTOR 3; TRANSCRIPTOME; TRASTUZUMAB; UBIQUITIN PROTEIN LIGASE E3; VIRUS RNA; ALPHA BETA INTERFERON RECEPTOR; IFNAR1 PROTEIN, MOUSE; MESSENGER RNA; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; RNA; TLR3 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ACTIVATION; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOFLUOROMETRY; FIBROSARCOMA; HISTOCOMPATIBILITY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEUKEMIA CELL; LEUKOCYTE ACTIVATION; MELANOMA; METASTASIS FREE SURVIVAL; MOUSE; MULTIPLE CYCLE TREATMENT; NEOADJUVANT CHEMOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RNA VIRUS; SARCOMA; SARCOMA CELL; VACCINIA VIRUS; VIRUS INFECTION; VIRUS VIRULENCE; XENOGRAFT; ADJUVANT THERAPY; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; C57BL MOUSE; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOCOMPETENCE; IMMUNOLOGY; METABOLISM; METASTASIS; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTHRACYCLINES; BREAST NEOPLASMS; CHEMOKINE CXCL10; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOCOMPETENCE; INTERFERON TYPE I; MICE, INBRED C57BL; MYXOVIRUS RESISTANCE PROTEINS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, PATTERN RECOGNITION; RNA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TREATMENT OUTCOME;

EID: 84913586780     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3708     Document Type: Article

References (72)

1. Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).
2. Tang, D., Kang, R., Coyne, C.B., Zeh, H.J. & Lotze, M.T. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev. 249, 158–175 (2012).
3. Hetz, C., Martinon, F., Rodriguez, D. & Glimcher, L.H. The unfolded protein response: integrating stress signals through the stress sensor IRE1a. Physiol. Rev. 91, 1219–1243 (2011).
4. Levine, B., Mizushima, N. & Virgin, H.W. Autophagy in immunity and inflammation. Nature 469, 323–335 (2011).
5. Zitvogel, L., Kepp, O. & Kroemer, G. Decoding cell death signals in inflammation and immunity. Cell 140, 798–804 (2010).
6. Matzinger, P. The danger model: a renewed sense of self. Science 296, 301–305 (2002).
7. Zitvogel, L., Kepp, O. & Kroemer, G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8, 151–160 (2011).
8. Panaretakis, T. et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 28, 578–590 (2009).
9. Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573–1577 (2011).
10. Ma, Y. et al. Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208, 491–503 (2011).
11. Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).
12. Apetoh, L. et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220, 47–59 (2007).
13. Senovilla, L. et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 337, 1678–1684 (2012).
14. González-Navajas, J.M., Lee, J., David, M. & Raz, E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12, 125–135 (2012).
15. Ma, Y. et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res. 74, 436–445 (2014).
16. Lim, E.S., Wu, L.I., Malik, H.S. & Emerman, M. The function and evolution of the restriction factor Viperin in primates was not driven by lentiviruses. Retrovirology 9, 55 (2012).
17. Hovanessian, A.G. et al. Identification of 69-kd and 100-kd forms of 2–5A synthetase in interferon-treated human cells by specific monoclonal antibodies. EMBO J. 6, 1273–1280 (1987).
18. Horisberger, M.A. Interferons, Mx genes, and resistance to influenza virus. Am. J. Respir. Crit. Care Med. 152, S67–S71 (1995).
19. Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded RNA–induced innate antiviral responses. Nat. Immunol. 5, 730–737 (2004).
20. Tareen, S.U. & Emerman, M. Human Trim5α has additional activities that are uncoupled from retroviral capsid recognition. Virology 409, 113–120 (2011).
21. Sen, G.C. & Fensterl, V. Crystal structure of IFIT2 (ISG54) predicts functional properties of IFITs. Cell Res. 22, 1407–1409 (2012).
22. Honda, K. et al. IRF-7 is the master regulator of type-I interferon–dependent immune responses. Nature 434, 772–777 (2005).
23. Ma, Y. et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38, 729–741 (2013).
24. Brahmer, J.R. et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
25. Foloppe, J. et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 15, 1361–1371 (2008).
26. Barbalat, R., Ewald, S.E., Mouchess, M.L. & Barton, G.M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185–214 (2011).
27. Goubau, D., Deddouche, S. & Reis, E.S.C. Cytosolic sensing of viruses. Immunity 38, 855–869 (2013).
28. Crawford, M.A. et al. Interferon-inducible CXC chemokines directly contribute to host defense against inhalational anthrax in a murine model of infection. PLoS Pathog. 6, e1001199 (2010).
29. Iwamoto, T. et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J. Natl. Cancer Inst. 103, 264–272 (2011).
30. Tabchy, A. et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin. Cancer Res. 16, 5351–5361 (2010).
31. Hatzis, C. et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. J. Am. Med. Assoc. 305, 1873–1881 (2011).
32. Desmedt, C. et al. Multifactorial approach to predicting resistance to anthracyclines. J. Clin. Oncol. 29, 1578–1586 (2011).
33. Horak, C.E. et al. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin. Cancer Res. 19, 1587–1595 (2013).
34. Popovici, V. et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 12, R5 (2010).
35. Allred, D.C., Harvey, J.M., Berardo, M. & Clark, G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11, 155–168 (1998).
36. Arriagada, R. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol. 44, 458–466 (2005).
37. Spielmann, M. et al. Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial. J. Clin. Oncol. 27, 6129–6134 (2009).
38. MacMicking, J.D. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat. Rev. Immunol. 12, 367–382 (2012).
39. Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732–738 (2001).
40. Tatematsu, M., Nishikawa, F., Seya, T. & Matsumoto, M. Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA. Nat. Commun. 4, 1833 (2013).
41. Shatz, M., Menendez, D. & Resnick, M.A. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 72, 3948–3957 (2012).
42. Bernard, J.J. et al. Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat. Med. 18, 1286–1290 (2012).
43. Van, D.N. et al. Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. FASEB J. 26, 3188–3198 (2012).
44. Ellermeier, J. et al. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 73, 1709–1720 (2013).
45. Salaun, B. et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 71, 1607–1614 (2011).
46. Conforti, R. et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 70, 490–500 (2010).
47. Schreiber, R.D., Old, L.J. & Smyth, M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
48. Vesely, M.D., Kershaw, M.H., Schreiber, R.D. & Smyth, M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011).
49. Lenci, R.E. et al. Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PLoS ONE 7, e50692 (2012).
50. + dendritic cells. J. Exp. Med. 208, 2005–2016 (2011).
51. Diamond, M.S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003 (2011).
52. + T-cell recruitment. Cancer Res. 69, 3077–3085 (2009).
53. Hong, M. et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 71, 6997–7009 (2011).
54. Eggermont, A.M. et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur. J. Cancer 48, 218–225 (2012).
55. Ruffell, B. et al. Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. USA 109, 2796–2801 (2012).
56. + follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873–2892 (2013).
57. Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105–113 (2010).
58. Weichselbaum, R.R. et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA 105, 18490–18495 (2008).
59. Chan, S.R. et al. STAT1-deficient mice spontaneously develop estrogen receptor α–positive luminal mammary carcinomas. Breast Cancer Res. 14, R16 (2012).
60. Yang, X. et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 25, 37–48 (2014).
61. Sheehan, K.C. et al. Blocking monoclonal antibodies specific for mouse IFN-α/β receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26, 804–819 (2006).
62. Uppaluri, R. et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation. 86, 137–147 (2008).
63. Gresser, I., Tovey, M.G., Maury, C. & Bandu, M.T. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J. Exp. Med. 144, 1316–1323 (1976).
64. Tovey, M.G., Begon-Lours, J. & Gresser, I. A method for the large scale production of potent interferon preparations. Proc. Soc. Exp. Biol. Med. 146, 809–815 (1974).
65. Gaj, T., Guo, J., Kato, Y., Sirk, S.J. & Barbas, C.F. III. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods 9, 805–807 (2012).
66. Galluzzi, L. et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 16, 1093–1107 (2009).
67. Galluzzi, L. et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Reports 2, 257–269 (2012).
68. Kepp, O., Galluzzi, L., Lipinski, M., Yuan, J. & Kroemer, G. Cell death assays for drug discovery. Nat. Rev. Drug Discov. 10, 221–237 (2011).
69. Criollo, A. et al. Mitochondrial control of cell death induced by hyperosmotic stress. Apoptosis 12, 3–18 (2007).
70. Schultze, J.L. & Eggle, D. IlluminaGUI: graphical user interface for analyzing gene expression data generated on the Illumina platform. Bioinformatics 23, 1431–1433 (2007).
71. Antonov, J. et al. Molecular risk assessment of BIG 1–98 participants by expression profiling using RNA from archival tissue. BMC Cancer 10, 37 (2010).
72. Gong, Y. et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 8, 203–211 (2007).